Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.
2.

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y.

Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Erratum in: Acta Diabetol. 2012 Jun;49(3):231.

PMID:
21898126
3.

Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.

Imai C, Saito M, Mochizuki K, Fuchigami M, Goda T, Osonoi T.

Metabolism. 2014 Jun;63(6):746-53. doi: 10.1016/j.metabol.2013.12.014.

PMID:
24559582
4.

Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.

Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y.

Endocr J. 2010;57(8):667-72. Erratum in: Endocr J. 2010;57(12):1089.

5.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9.

PMID:
16912128
6.

Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.

Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, Ochi F, Kusunoki Y, Tokuda M, Murai K, Hamaguchi T, Namba M.

Endocr J. 2011;58(10):869-77.

7.

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.

Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK.

Endocr Pract. 2013 Jan-Feb;19(1):19-28. doi: 10.4158/EP12100.OR.

PMID:
23186950
8.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
9.
10.

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.

Aaboe K, Akram S, Deacon CF, Holst JJ, Madsbad S, Krarup T.

Diabetes Obes Metab. 2015 Jan;17(1):74-81. doi: 10.1111/dom.12395.

PMID:
25243647
11.

Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.

Tsuchimochi W, Ueno H, Yamashita E, Tsubouchi C, Sakoda H, Nakamura S, Nakazato M.

Endocr J. 2015;62(1):13-20. doi: 10.1507/endocrj.EJ14-0393.

12.

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K.

Cardiovasc Diabetol. 2012 Aug 6;11:92. doi: 10.1186/1475-2840-11-92.

13.

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.

Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2013 Mar;15(3):237-40. doi: 10.1089/dia.2012.0214.

PMID:
23402316
14.

Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.

Okada K, Yagyu H, Kotani K, Yamazaki H, Ozaki K, Takahashi M, Nagashima S, Osuga J, Ishibashi S.

Endocr J. 2013;60(7):913-22.

15.

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.

Clin Ther. 2013 Mar;35(3):273-285.e7. doi: 10.1016/j.clinthera.2013.01.010.

PMID:
23433601
17.
18.

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.

Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA.

Diabetes. 2014 Feb;63(2):663-74. doi: 10.2337/db13-0805.

19.

Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".

Mikada A, Narita T, Yokoyama H, Yamashita R, Horikawa Y, Tsukiyama K, Yamada Y.

Diabetes Res Clin Pract. 2014 Dec;106(3):538-47. doi: 10.1016/j.diabres.2014.09.040.

PMID:
25451890
20.

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.

Solis-Herrera C, Triplitt C, Garduno-Garcia Jde J, Adams J, DeFronzo RA, Cersosimo E.

Diabetes Care. 2013 Sep;36(9):2756-62. doi: 10.2337/dc12-2072.

Items per page

Supplemental Content

Support Center